Form 4: CEO Leon O. Moulder Jr. Increases Stake in Zenas BioPharma
Insider Transaction Report
Zenas BioPharma CEO Leon O. Moulder Jr. purchased 60,000 shares of common stock at a weighted average price of $16.88.
Summary
- CEO Leon O. Moulder Jr. acquired 60,000 shares of Zenas BioPharma (ZBIO) common stock.
- The purchase was executed on May 18, 2026, at a weighted average price of $16.88 per share.
- The shares were purchased in multiple transactions ranging from $16.59 to $16.97.
- Following the transaction, the reporting person holds 423,155 shares directly and maintains indirect interests through a trust and Tellus BioVentures LLC.
Sentiment
Score: 8
Explanation: StockSavvy.ai views this as a positive indicator, as significant open-market purchases by a CEO typically suggest strong internal confidence in the company's future prospects.
Positives
- Insider confidence is demonstrated by the CEO's open-market purchase of company stock.
- The purchase reflects alignment between executive leadership and shareholder interests.
Negatives
- None identified in this filing.
Risks
- Market volatility affecting the value of the acquired shares.
- General risks associated with the biotechnology sector and clinical-stage development.
Future Outlook
The filing does not contain forward-looking guidance regarding company operations or financial performance.
Industry Context
StockSavvy.ai notes that insider buying by a CEO is generally viewed as a positive signal of management's belief in the company's long-term valuation and pipeline potential, particularly in the volatile biotech sector.
Comparison to Industry Standards
- Insider purchases by CEOs are a standard practice in the biotech industry to signal confidence during development phases.
- The scale of the purchase is consistent with typical executive equity accumulation patterns.
Related Party Transactions
- The reporting person is the Trustee of the Leon O. Moulder, Jr. Revocable Trust.
- The reporting person is the Managing Member of Tellus BioVentures LLC.
Stakeholder Impact
- Shareholders may interpret this purchase as a vote of confidence in the company's strategic direction.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 05/18/2026 | Date of the reported stock purchase transaction. |
Keywords
Zenas BioPharma, ZBIO, Insider Trading, Leon O. Moulder Jr., Biotech, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.